Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q969E8
UPID:
TSR2_HUMAN
Alternative names:
-
Alternative UPACC:
Q969E8
Background:
Pre-rRNA-processing protein TSR2 homolog plays a crucial role in the early stages of ribosome biogenesis, specifically in 20S pre-rRNA processing. This protein's involvement in the fundamental process of ribosome assembly underscores its importance in cellular biology and protein synthesis.
Therapeutic significance:
The protein is linked to Diamond-Blackfan anemia 14, with mandibulofacial dysostosis, a condition characterized by congenital non-regenerative hypoplastic anemia and various congenital anomalies. Understanding the role of Pre-rRNA-processing protein TSR2 homolog could open doors to potential therapeutic strategies for this rare and complex disease.